Biotechnology

A Calgary startup's revolutionary wound care gel, already used in hospitals, is now being funded by the government for battlefield trauma applications.

A financially struggling healthcare firm makes a bold leap into neurotechnology, but can it compete with giants like Neuralink in the high-risk BCI race?

A new long-term deal for the INTERCEPT system highlights a critical shift towards proactive pathogen reduction to protect France's blood supply from global threats.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

In a key human trial, Sona Nanotech's heat-based therapy saw a 60% complete response in tumors for melanoma patients who had exhausted other options.

NerView Surgical's NerveSense™ wins FACIT's top award, spotlighting a growing ecosystem making Ontario a global leader in oncology innovation.

By emphasizing deep anatomical knowledge, Medytox aims to elevate industry standards and solidify its leadership in Asia's booming medical aesthetics market.

BrioHealth Solutions gets an FDA nod for a trial of its BrioVAD, a miniaturized heart pump designed for children with advanced heart failure.

A revolutionary organ preservation system is showing 100% graft survival in new studies, promising to expand the donor pool for children in need.

CHINAPLAS 2026 preview reveals a strategic shift to bio-materials, smart factories, and deep alignment with China's ambitious industrial roadmap.

H1 launched its Site Network Suite, an AI platform promising to slash clinical trial feasibility times and reshape how sponsors and research sites connect.

With its CMO and CSO now both recipients of the AHA's top honor, Cardiovascular Clinical Sciences signals a rare concentration of elite expertise.

A new non-viral gene therapy targeting iron buildup in the eye has completed its Phase I trial, offering a potential new path for millions with dry AMD.

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

ENA Respiratory appoints GSK veteran Melissa Faris to its board, a strategic move signaling an accelerated push for its innovative virus-agnostic nasal spray.

Canadian giant Apotex acquires Cumberland's U.S. branded drugs for $100M, a move that expands its hospital presence and pivots Cumberland to a biotech.

Backed by military funding, a novel protein therapy that actively grows bone has finished a key clinical trial, promising to revolutionize dental surgery.

Korean brand Dr. Reju-All's pharmacist-led approach and PDRN science captivated nearly 5,000 dermatologists, signaling a new wave in U.S. skincare.

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

RIMAN rallies 2,000 in Macau, unveiling a $3M bio-material and a bold strategy to dominate the competitive APAC K-beauty direct selling market.